Efficacy and Safety of 2 Doses of TEV-48125 Versus Placebo for the Prevention of Chronic Migraine

Study Title
Comparing Efficacy and Safety of 2 Dose Regimens of Subcutaneous Administration of TEV-48125 Versus Placebo for the Preventive Treatment of Chronic Migraine
Teva Identifier
TV48125-CNS-30049 | 2015-004549-23
ClinicalTrials.gov Identifier
NCT02621931
Study Status
Completed
Trial Condition(s)
Migraine
Interventions
Drug: Fremanezumab | Drug: Placebo

Study Description

Please refer to ClinicalTrials.gov for a description of the trial
Print

Click for participation criteria and map of study locations


Key Participation Requirements

Gender
Female, Male
Age Range
18 Years to 70 Years
Trial Duration
March 22, 2016 - April 11, 2017
Phase
Phase 3

Study Type

Interventional